Class / Patent application number | Description | Number of patent applications / Date published |
424930720 | Platelet | 85 |
20080213238 | Lyophilized platelet rich plasma for the use in wound healing (chronic or acute) and bone or tissue grafts or repair - This invention relates to an improved Lyophilized platelet rich plasma used to make a platelet gel wound healant, and methods of preparation and use thereof for healing wounds are disclosed. The improved wound healant comprises therapeutically effective amounts of activated growth factors, platelet ghost, plasma (know as the plasma back bone), white blood cells with optional none, one or more additional anti-oxidant such as vitamin A and/or C and/or E, and/or none one or more antibiotics and/or GHK-Cu (produced by ProCyte Inc.) | 09-04-2008 |
20080267936 | Treatment of trauma-hemorrhage with short oligopeptides - Described are methods and associated means for treating a subject, such as a mammal, experiencing or thought to be at risk for hemorrhagic shock. Such methods include administering to the subject in a medically acceptable manner, a short oligopeptide such as AQGV (SEQ ID NO:1) and/or LQGV (SEQ ID NO:2). | 10-30-2008 |
20090035289 | DRY PLATELET COMPOSITION - The invention features a dry platelet composition and methods of making and using the freeze-dried platelet composition. | 02-05-2009 |
20090041737 | COLD STORAGE OF MODIFIED PLATELETS - A method for storing and using platelets and an associated platelet structure. At least one modified platelet is formed. Each modified platelet includes a platelet and at least one polymerated chemical. Each polymerated chemical includes a polymer covalently bonded directly to the platelet or includes the polymer and a linker molecule such that the linker molecule is covalently bonded to the platelet and the polymer is covalently attached to the linker molecule. The polymer of each polymerated chemical of each modified platelet is polyethylene glycol (PEG) or a PEG derivative. Forming each modified platelet does not include modifying the platelet membrane of each platelet with a glycan-modifying agent. The at least one modified platelet is stored in a temperature range below 0° C. After being stored, the at least one modified platelet may be introduced into a subject to treat a condition related to a reduced platelet function. | 02-12-2009 |
20090074737 | COMPOSITIONS AND METHODS FOR PROLONGING SURVIVAL OF PLATELETS - The present invention provides modified platelets having a reduced platelet clearance and methods for reducing platelet clearance. Also provided are compositions for the preservation of platelets. The invention also provides methods for making a pharmaceutical composition containing the modified platelets and for administering the pharmaceutical composition to a mammal to mediate hemostasis. | 03-19-2009 |
20090169532 | CURABLE BONE CEMENT - The present invention describes a curable bone cement. The cement comprises a curable polymeric binder and a filler, and is capable of curing without substantial evolution of heat on exposure to a curing agent. The binder comprises phenol groups which are capable of reacting in order to cure the cement. | 07-02-2009 |
20090220474 | NOVEL A-GALACTOSIDASES - This invention relates to novel α-galactosidases for the enzymatic removal of the immunodominant monosaccharides on blood products and tissues. Specifically this invention provides a novel family of α3 glycosidases, used for the enzymatic removal of type B antigens from blood group B and AB reactive blood products, and the GaIiIi antigen from non-human animal tissues, thereby converting these to non-immunogenic cells and tissues suitable for transplantation. | 09-03-2009 |
20090220475 | BONE REPAIR MATERIAL - The bone repair material comprises the following components: | 09-03-2009 |
20100143317 | INFARCT AREA PERFUSION-IMPROVING COMPOSITIONS AND METHODS OF VASCULAR INJURY REPAIR - The described invention provides pharmaceutical compositions for treating an infarct area injury and methods of treating or repairing the infarct area injury in a revascularized subject in the aftermath of an acute myocardial infarction resulting from a natural disease process by administering to the subject parenterally through a catheter a sterile pharmaceutical composition containing a therapeutically effective amount of a nonexpanded sterile isolated chemotactic hematopoietic stem cell product as a first therapeutic agent and optionally a therapeutically effective amount of at least one compatible second therapeutic agent. The infarct area-improving amount of the sterile isolated chemotactic hematopoietic stem cell product comprises an enriched population of isolated autologous CD34+ cells containing a subpopulation of potent cells expressing CXCR-4 and having CXCR-4-mediated chemotactic activity such that the enriched population of isolated autologous CD34+ hematopoietic stem cells provides at least 0.5×10 | 06-10-2010 |
20100150892 | PF4-DEPLETED PLATELET CONTAINING BLOOD PREPARATIONS AND RELATED KITS, DEVICES AND METHODS FOR HARD AND SOFT TISSUE REPAIR - Methods of repairing and regenerating hard or soft tissue and reducing inflammation, anti-angiogenesis and anti-osteogenesis in a mammal and related methods of removing PF4 from platelets containing blood preparations. In one embodiment, the method comprises administering to a mammal platelets containing blood preparation where the PF4 has been reduced from the platelet containing blood preparation to repair and regenerate hard and soft tissue in the mammal. | 06-17-2010 |
20100221233 | COMPOSITIONS AND METHODS FOR ENHANCING NEUROPROTECTION VIA ADMINISTRATION OF STEM CELLS AND BLOOD BRAIN BARRIER PERMEABILIZERS - The present invention provides compositions and methods for enhancing the neuroprotective effect of umbilical cord blood cells. More particularly, the present invention provides methods of treating neurodegenerative disorders by administering umbilical cord blood cells and a substance capable of permeabilizing the blood brain barrier. In one embodiment, the blood brain barrier permeabilizer is mannitol. In another embodiment, the blood brain barrier permeabilizer is Cereport. | 09-02-2010 |
20100226902 | Method For Treating Wounds With Enriched Platelet Wound Healant - An improved method for treating wounds with an enriched platelet composition is provided in which a small amount of a patient's blood is used to prepare, at point-of-care, a platelet-rich plasma (PRP) from which a gel is produced. The method involves the use of improved materials to improve the ease and speed at which wounds may be treated at the point-of-care. | 09-09-2010 |
20100226903 | METHOD OF DELIVERING CELL THERAPY TO A TARGET SITE - A method of delivering therapy to a target site. The method includes (a) obtaining a base image of the target site, (b) injecting a dose of a mix of a therapeutic agent and a contrast agent into a first injection location at the target site via a needle passing through a catheter, (c) collecting sequential fluoroscopic images of a contrast agent dispersion cloud at the first injection location, (d) determining a contrast agent dispersion area from the sequential fluoroscopic images, (e) determining a therapeutic agent dispersion area from the contrast agent dispersion area, (f) marking the therapeutic agent dispersion area on the base image of the target site, and (g) repeating (b) through (f) until the target site is substantially covered with overlapping therapeutic agent dispersion areas corresponding to a plurality of injections at a plurality of injection locations at the target site. | 09-09-2010 |
20110123503 | PLATELET FRACTION DERIVING FROM PLACENTAL BLOOD - The present invention relates to platelet fractions which can be obtained from placental blood, with high concentrations of platelet factors as well as gels and lysates deriving therefrom. The invention further relates to methods for preparing said platelet fractions from placental blood, and to the uses thereof as such or as platelet gels or as lysates. | 05-26-2011 |
20110189151 | COMPOSITIONS AND METHODS FOR PROLONGING SURVIVAL OF PLATELETS - The present invention provides modified platelets having a reduced platelet clearance and methods for reducing platelet clearance. Also provided are compositions for the preservation of platelets. The invention also provides methods for making a pharmaceutical composition containing the modified platelets and for administering the pharmaceutical composition to a mammal to mediate hemostasis. | 08-04-2011 |
20110318319 | ACTIVATION and AGGREGATION OF HUMAN PLATELETS AND FORMATION OF PLATELET GELS BY NANOSECOND PULSED ELECTRIC FIELDS - Methods for forming activated platelet gels using nsPEF's and applying the activated gels to wounds, such as heart tissue after myocardial infarction. The platelets are activated by applying at least one nsPEF with a duration between about 10 picoseconds to 1 microsecond and electrical field strengths between about 10 kV/cm and 350 kV/cm. | 12-29-2011 |
20120014933 | Method for Producing Platelets - The present invention relates to a method for producing platelets from mature megakaryocytes. More particularly, the invention relates to an ex vivo method for producing platelets, from mature megakaryocytes, said method comprising a step of subjecting a suspension of mature megakaryocytes to a flow having a minimal shear rate of 600 s | 01-19-2012 |
20120027740 | METHOD AND MEANS FOR PRODUCING TISSUES AND TISSUES OBTAINED - A method regenerates specific tissue, preferably mesenchymal tissues like bone, fat, tendon, muscle, cartilage and marrow stroma and hematological tissue (RBC, WBC, platelets, lymphocytes, hematological stem cells (HSC), endothelial progenitor cells (EPC) etc.). A method for reconstructing, regenerating, rejuvenating or reinforcing a damaged or diseased tissue in a mammal subject, and preferably a human patient, uses a (regenerated) tissue obtained by this method. | 02-02-2012 |
20120045424 | ASSEMBLY, DEVICE KIT AND METHOD FOR PREPARING PLATELET-RICH PLASMA (PRP) - An assembly comprising: (a) a test tube for receiving a blood sample or a platelet-comprising fraction thereof and for obtaining therein, by a procedure that includes centrifugation, a platelet rich plasma (PRP) fraction; (b) an elongated filter device having a first and second end and a lumen extending there between, and having a filter fitted at the first end, the filter having a effective pore size such to permit passage of platelets and not permit passage of white blood cells (WBC) larger than a defined size into the lumen, the second end having an opening; the first end of the elongated filter device being adapted for tight fitting into said test tube such that when forced into the test tube to exert pressure on the PRP fraction, the PRP fraction with the platelets filters into said lumen and white blood cells of a size large than said defined size remain in the test tube to thereby obtain a WBC-selective PRP within said lumen. | 02-23-2012 |
20120070420 | COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC AND NEURODEGENERATIVE DISORDERS - Treatment methods are disclosed for psychiatric and neurodegenerative disorders by treatment of the patient with platelet-rich plasma (PRP). PRP is administered to areas of the brain that have been identified as associated with the psychiatric or neurodegenerative disorder to replenish the dysfunctional tissue. | 03-22-2012 |
20120082652 | METHODS AND DEVICES FOR COLLECTING SEPARATE COMPONENTS OF WHOLE BLOOD - A method provides for procuring platelet rich plasma (PRP) from a sample of whole blood in a vial. The method includes the steps of: separating the whole blood into layers through centrifugation with an upper layer containing platelet poor plasma (PPP) and a PRP layer below the upper layer containing PRP; adjusting an end point of a first range of motion of an extractor relative to a position of the PRP layer; moving the extractor through the first range of motion through the vial, PPP passing out from the upper layer through the extractor; and after the extractor reaches the end point of the first range of motion, extracting the PRP through the extractor and collecting the PRP. | 04-05-2012 |
20120087903 | Hair growth agent having a platelet dry powder - A hair growth agent having an effective dose of a platelet dry powder and a pharmaceutically acceptable solvent and/or excipient, wherein the effective dose refers to the presence of at least 1,000 platelets in every milligram of the hair growth agent. | 04-12-2012 |
20120093793 | Methods of Preventing Platelet Alloimmunization and Alloimmune Platelet Refractoriness and Induction of Tolerance in Transfused Recipients - Methods and compositions for the prevention or reduction of platelet transfusion associated complications are provided. Methods are provided to modify donor platelets prior to transfusion to prevent or reduce alloimmune platelet refractoriness. | 04-19-2012 |
20120128647 | DELIVERY OF COMPOUNDS WITH REHYDRATED BLOOD CELLS - Fixed-dried blood cells carrying an active agent are described, along with methods of making the same, methods of using the same, and compositions containing the same. The blood cells are preferably blood platelets. | 05-24-2012 |
20120134974 | METHODS FOR REMOVING PLASMA - A method for preparing a blood component composition for reducing risk of transfusion related injury includes passing a blood component composition through a tangential flow filter unit comprising one or more filter membranes. A diafiltration solution is added to the blood component composition during the filtration process. Non-cellular plasma components, including antibodies, are removed from the blood component composition by the tangential flow filtration. | 05-31-2012 |
20120156184 | METHODS AND MATERIALS FOR TREATING BURN INJURIES - This document provides methods and materials involved in treating burn injuries. For example, methods and materials for using skin grafts (e.g., autologous skin grafts) treated with an autologous platelet concentrate and autologous thrombin to treat burn injuries (e.g., deep skin burn injuries) are provided. | 06-21-2012 |
20120171179 | APPARATUS, SYSTEM, AND METHOD FOR COMPOSITIONS AND METHODS FOR TREATING, PREVENTING, OR ALLEVIATING BONE OR CARTILAGE DISEASES - The present invention provides pharmaceutical compositions, and methods of preparation and use for the treatment, prevention or alleviation of bone and cartilage diseases. The present invention discloses a method and a pharmaceutical composition comprising adipose-derived stem cells, platelet rich plasma, calcium chloride, and hyaluronic acid for the treatment, prevention, or alleviation of bone diseases, and a method and a pharmaceutical composition further comprising dexamethasone for the treatment, prevention, or alleviation of cartilage diseases. | 07-05-2012 |
20120171180 | COMPOSITIONS COMPRISING AMNION DERIVED ADHERENT CELLS AND PLATELET-RICH PLASMA - Provided herein are methods of using amnion derived adherent cells, and populations of, and compositions comprising, such cells, in the modulation of an immune response. In various embodiments, the immune response is graft-versus-host disease, an allergy, asthma, or an immune-related disease or disorder, e.g., an autoimmune disease. | 07-05-2012 |
20120171181 | COMPOSITIONS AND MINIMALLY INVASIVE METHODS FOR TREATING CANCER - Methods are described for using compositions containing platelet-rich plasma for the treatment of a cancer in a variety of tissues. Particularly, treatment of brain cancer with platelet releasate is described. | 07-05-2012 |
20120171182 | METHODS AND COMPOSITIONS FOR THE TREATMENT, PREVENTION, AND ALLEVIATION OF BONE AND CARTILAGE DISEASES OR INJURIES AND HAIR LOSS - The present invention provides pharmaceutical compositions, and methods of preparation and use for the treatment, prevention or alleviation of bone and cartilage diseases or injuries and hair loss. The present invention discloses a method and a pharmaceutical composition comprising mesenchymal stem cells, platelets, activating factors and scaffolding materials for the treatment, prevention, or alleviation of bone diseases, bone injuries or hair loss, and a method and a pharmaceutical composition further comprising dexamethasone for the treatment, prevention, or alleviation of cartilage diseases or injuries. | 07-05-2012 |
20120183520 | MINIMALLY INVASIVE METHODS FOR TREATING DYSFUNCTION OF CARDIAC MUSCLE - Methods are described for using compositions containing platelet-rich plasma for the treatment of acute or chronic dysfunction of cardiac muscle. The method may employ a kit which includes a platelet-rich plasma composition and a pH adjusting agent and a catheter or syringe for delivery of the platelet-rich plasma composition to dysfunctional cardiac muscle. The kit may also include a syringe for withdrawing blood from a patient and a centrifuge device means to obtain platelet-rich plasma. | 07-19-2012 |
20120213755 | SEMI-SYNTHETIC PLATELET GEL AND METHOD FOR THE PREPARATION THEREOF - A semi-synthetic platelet gel comprising a platelet-rich plasma, at least one platelet activator, and a biocompatible polymer selected from the group comprising carbomers, polyalkylene glycols, poloxamers, polyesters, polyethers, polyanhydrides, polyacrylates, polyvinyl acetates, polyvinyl pyrrolidones, polysaccharides, and derivatives thereof. | 08-23-2012 |
20120225044 | COMPOSITIONS AND METHODS FOR PROLONGING SURVIVAL OF PLATELETS - The present invention provides modified platelets having a reduced platelet clearance and methods for reducing platelet clearance. Also provided are compositions for the preservation of platelets. The invention also provides methods for making a pharmaceutical composition containing the modified platelets and for administering the pharmaceutical composition to a mammal to mediate hemostasis. | 09-06-2012 |
20120230967 | DEVICE AND METHOD TO ACTIVATE PLATELETS - The present invention includes a method for activating platelets in a platelet solution, the method may include passing the platelet solution through an activator at least once to activate at least one of the platelets in the platelet solution to produce an activated platelet solution. The activator may further include a flow disruption element. The method may further induce administering the activated platelet solution to the repair site of a patient. The present invention may also be a system for treating a medical condition at a repair site within a patient in need thereof, which may include a platelet solution container for housing a platelet solution; an activator to activate at least one platelet; and an introducer to direct the at least one activated platelet to the repair site. | 09-13-2012 |
20120230968 | WOUND HEALANT SYSTEM AND METHODS OF USE - Provided herein are compositions for treating wounds, method of making and using the system thereof. The system for treating a wound includes a first composition having cetylpyridinium chloride, | 09-13-2012 |
20120237490 | SYSTEMS AND METHODS FOR AUTOLOGOUS BIOLOGICAL THERAPEUTICS - This disclosure describes systems, methods, and apparatus for forming concentrates of platelet-rich plasma or bone marrow cells having user-defined concentrations, concentration ranges, and/or volumes. Whole blood or bone marrow samples can be passed through one or two separation operations in which platelets or bone marrow cells are separated from red blood cells and concentrated in a plasma. During this separation and concentrating, a total number of platelets or bone marrow cells or a concentration of either is determined and then used to ascertain what volumes and concentrations need be mixed in order to produce a platelet-rich plasma concentrate or a bone marrow-rich plasma concentrate having a target concentration and/or volume. | 09-20-2012 |
20120258086 | PLATELET SOLUTION FOR USE IN JOINT SURGERY - The invention is directed to a method of accelerating healing in a joint comprising administering a platelet composition to the joint. | 10-11-2012 |
20120294842 | Platelet Additive Solution Having a Sialidase Inhibitor - The present invention relates to a platelet additive solution (PAS) having an amount of one or more sialidase inhibitors and optionally one or more glycan-modifying agents; and one or more of PAS components that includes a salt, a citrate source, a carbon source, and any combination thereof. | 11-22-2012 |
20120308540 | Modified factor IX polypeptides and uses thereof - Modified Factor IX (FIX) polypeptides and uses thereof are provided. Such modified FIX polypeptides include FIXa and other forms of FIX. Among the modified FIX polypeptides provided are those that have altered activities, typically altered procoagulant activity, including increased procoagulant activities. Hence, such modified polypeptides are therapeutics. | 12-06-2012 |
20120321601 | Increased In Vivo Circulation Time of Platelets After Storage With A Sialidase Inhibitor - The present invention relates to methods, compositions and kits for increasing the in vivo circulation time of isolated platelets by storing the platelets with one or more sialidase inhibitors. | 12-20-2012 |
20130004473 | Methods and Biomarkers for the Detection of Dengue Hemorrhagic Fever - The present invention provides methods for detecting, analyzing, and identifying biomolecules used to identifying patient with dengue-like symptom who are at risk of DHF. The inventive method comprises detecting in a sample from a subject dengue infected patient one or more biomarkers selected from the group consisting of IL-10, fibrinogen, C4A, immunoglobulin, tropomyosin, and three isoforms of albumin, and which are used in a predictive MARS model to detect patients with risk of developing DHF. | 01-03-2013 |
20130004474 | SOLUBLE PHYSIOLOGICAL CHITOSAN FORMULATIONS COMBINED WITH PLATELET-RICH PLASMA (PRP) FOR TISSUE REPAIR - The present disclosure relates to an activated polymer composition for use in repairing tissue of a patient comprising platelet-rich plasma (PRP), a chitosan solution, a salt such as NaCl or glycerol phosphate, and an activator such as at least one of CaCI | 01-03-2013 |
20130039896 | PHARMACEUTICAL KITS COMPRISING MESENCHYMAL STEM CELLS - A method of treating a natural soft skeletal tissue injury in a patient the method comprising administering to the patient a composition of mesenchymal stem cells in liquid suspension enriched compared to the natural source of said cells, or tenocytes derived therefrom. The method is particularly suited to the regeneration of tendons in competitive mammals, such as the superficial digital flexor tendon of the horse. | 02-14-2013 |
20130045192 | REAGENTS AND METHODS FOR DETECTING PNH TYPE II WHITE BLOOD CELLS AND THEIR IDENTIFICATION AS RISK FACTORS FOR THROMBOTIC DISORDERS - The disclosure relates to methods for detecting PNH Type II cell populations in biological samples as well as methods for determining whether a patient is at an increased risk for developing thrombocytopenia or thrombosis based on the percentage of PNH Type II cells in the patient's blood. The disclosure also features reagents and conjugates for use in the methods. | 02-21-2013 |
20130095087 | ABSORBABLE IN SITU GEL-FORMING SYSTEM, METHOD OF MAKING AND USE THEREOF - An in situ gel-forming composition is disclosed. The in situ gel-forming composition comprises one or more absorbable polymers, solvents such as N-methyl-2-pyrrolidone, polyethylene glycol or DMSO, and optionally one or more bioactive agent. The composition forms a hydrogel or semi-solid mass on contact with an aqueous environment. The method of using in situ gel-forming composition for various applications is also disclosed. | 04-18-2013 |
20130177541 | Modified factor IX polypeptides and uses thereof - Modified Factor IX (FIX) polypeptides and uses thereof are provided. Such modified FIX polypeptides include FIXa and other forms of FIX. Among the modified FIX polypeptides provided are those that have altered activities, typically altered procoagulant activity, including increased procoagulant activities. Hence, such modified polypeptides are therapeutics. | 07-11-2013 |
20130287753 | Compositions and Methods for Cartilage Repair - Autologous compositions and methods are provided for cartilage repair in patients in need thereof. Some aspects include combinations of platelet-based materials with chondrogenesis inducing agents in the presence or absence of cell-based therapies. | 10-31-2013 |
20130309214 | COMPOSITION CONTAINING INJECTABLE SELF-HARDENED APATITE CEMENT - A method of producing an injectable calcium phosphate paste by a process in which calcium phosphate precursors are mixed with the setting fluids to form a self-hardened apatite cement is disclosed. The produced apatite cement is biocompatible, bioactive and biodegradable in the body. The pH value of said apatite cement is approximately 7 with compressive strength between 10-30 MPa and the setting process will not generate.temperature >37° C. The self-hardened apatite (SHA) cement is found to be bioresorbable and can be used for bone fillers, fixation of broken bones or artificial joints in human and also appropriate for use as a delivery vehicle. | 11-21-2013 |
20130344047 | Methods And Composition For Treating Heart Failure And Ischemia - Methods and compositions for treating heart failure by administration of beneficial agents to the heart. | 12-26-2013 |
20140050711 | PRODUCTION OF RED BLOOD CELLS AND PLATELETS FROM STEM CELLS - This disclosure provides methods of making a megakaryocyte-erythroid progenitor cell (MEP), comprising differentiating a stem cell into a MEP in culture in the presence of an aryl hydrocarbon receptor (AhR) agonist. In some embodiments the stem cell is a pluripotent stem cell. In some embodiments the MEP co-expresses CD41 and CD235. In some embodiments the number of MEPs produced in the culture increases exponentially. Methods of making a red blood cell (RBC) by culturing a MEP in the presence of an AhR agonist are also provided. Methods of making a megakaryocyte and/or a platelet, comprising culturing a MEP in the presence of an AhR modulator are also provided. In some embodiments the AhR modulator is an AhR antagonist. This disclosure also provides compositions comprising at least 1 million MEPs per ml and compositions in which at least 50% of the cells are MEPs. | 02-20-2014 |
20140056865 | ADIPOSE COMPOSITION SYSTEMS AND METHODS - Embodiments of the present invention encompass compositions containing an adipose derived carrier, matrix, or filler, in some cases optionally in combination with bone particles or other granular materials or substances, for delivery to a human patient. Methods of manufacture and use of such adipose derived compositions are also disclosed. | 02-27-2014 |
20140065119 | METHODS AND COMPOSITIONS COMPRISING CYCLIC ANALOGUES OF HISTATIN 5 FOR TREATING WOUNDS - Compositions and methods for treating wounds are provided. The compositions include cyclic analogues of histatin (5). | 03-06-2014 |
20140065120 | DELIVERY OF COMPOUNDS WITH REHYDRATED BLOOD CELLS - Fixed-dried blood cells carrying an active agent are described, along with methods of making the same, methods of using the same, and compositions containing the same. The blood cells are preferably blood platelets. | 03-06-2014 |
20140065121 | BLOOD PLASMA BASED HYDROGELS FOR TISSUE REGENERATION AND WOUND HEALING APPLICATIONS - The present disclosure generally relates to tissue engineering and wound healing. More particularly, the present disclosure relates to the modification of plasma with a stability conferring agent to create a hydrogel for use in regenerative medicine and other tissue engineering applications. | 03-06-2014 |
20140086891 | COMPOSITIONS AND METHODS FOR PROMOTING TISSUE REGENERATION - Provided are compositions for promoting bone and cartilage growth. In certain embodiments, tissue graft compositions comprising a polymeric scaffold (e.g., PLGA), hyaluronic acid, and substantially purified mononucleated cells derived from bone marrow aspirate. In various embodiments, the tissue graft composition may comprise thrombin. The tissue grafts may be used to promote bone growth, e.g., in a spinal fusion operation. | 03-27-2014 |
20140099293 | METHOD FOR EX-VIVO SEPARATION OF APOPTOTIC CHROMATIN FRAGMENTS FROM BLOOD OR PLASMA FOR PREVENTION AND TREATMENT OF DIVERSE HUMAN DISEASES - A method of prevention/treatment of pathological consequences of DNA damage triggered by incorporation of circulating apoptotic chromatin fragments into healthy cells of individuals/patients in need therefore, said method comprising ex vivo or extra corporeal treatment of blood/plasma for removal of circulating chromatin fragments released from apoptotic cells which apoptotic chromatin fragments are capable of triggering DNA damage leading to genomic instability, senescence, apoptosis and cancerous transformation of healthy cells on being integrated into their genomes | 04-10-2014 |
20140105876 | CERAMIC BIOCOMPOSITE FOR BONE REGENERATION - The invention relates to a ceramic biocomposite for bone regeneration, having a pH range of between 6.5 and 8.5, with an initial plasticity that allows the biocomposite to be easily moulded in situ and to set after 7 minutes, meaning that it can remain at the indicated location during the healing process. In addition, the biocomposite has demonstrated an ability to stimulate bone formation in hard-to-heal wounds. The material can act alone or in combination with other types of bone graft such as autografts, homografts or xenografts which act as a vehicle, as a binding material for endosseous prostheses or as a covering for endosseous implants or prostheses. | 04-17-2014 |
20140186320 | METHODS AND COMPOSITIONS FOR THE TREATMENT, PREVENTION, AND ALLEVIATION OF BONE AND CARTILAGE DISEASES OR INJURIES AND HAIR LOSS - The present invention provides pharmaceutical compositions, and methods of preparation and use for the treatment, prevention or alleviation of bone and cartilage diseases or injuries and hair loss. The present invention discloses a method and a pharmaceutical composition comprising mesenchymal stem cells, platelets, activating factors and scaffolding materials for the treatment, prevention, or alleviation of bone diseases, bone injuries or hair loss, and a method and a pharmaceutical composition further comprising dexamethasone for the treatment, prevention, or alleviation of cartilage diseases or injuries. | 07-03-2014 |
20140205582 | MEGAKARYOCYTE PROGENITOR CELLS FOR PRODUCTION OF PLATELETS - Provided herein are methods of generating megakaryocyte lineage cells from hematopoietic stem cells in the absence of feeder cells and serum. The megakaryocyte progenitor cells (MKPs) generated as described result in rapid production of significant numbers of platelets when administered in vivo. | 07-24-2014 |
20140212399 | HAIR GROWTH AGENT HAVING A PLATELET DRY POWDER - A hair growth agent having an effective dose of a platelet dry powder and a pharmaceutically acceptable solvent and/or excipient, wherein the effective dose refers to the presence of at least 1,000 platelets in every milliliter of the hair growth agent. | 07-31-2014 |
20140242054 | METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY CONDITIONS USING PLATELET ENRICHED PLASMA - Described herein are methods and compositions for the treatment of respiratory diseases such as, for example, exercise induced pulmonary hemorrhage. The methods include the use of compositions comprising platelet enriched plasma, for example, platelet rich plasma and/or platelet poor plasma, for treatment of respiratory diseases in humans and animals, in particular, equines, by administration to the respiratory system. | 08-28-2014 |
20140271589 | TREATMENT OF COLLAGEN DEFECTS USING PROTEIN SOLUTIONS - Methods of stimulating collagen production, including stimulation of chondrocyte production, at the site of a defect. Methods include administering to the site of a defect at least two proteins from the group IL-1ra, sTNF-RI, sTNF-RII, IGF-I, EGF, HGF, PDGF-AB, PDGF-BB, VEGF, TGF-β1, and sIL-1RII. | 09-18-2014 |
20140271590 | METHODS FOR PRODUCTION OF PLATELETS FROM PLURIPOTENT STEM CELLS AND COMPOSITIONS THEREOF - Methods for production of platelets from pluripotent stem cells, such as human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) are provided. These methods may be performed without forming embryoid bodies or clusters of pluripotent stem cells, and may be performed without the use of stromal inducer cells. Additionally, the yield and/or purity can be greater than has been reported for prior methods of producing platelets from pluripotent stem cells. Also provided are compositions and pharmaceutical preparations comprising platelets, preferably produced from pluripotent stem cells. | 09-18-2014 |
20140294794 | METHODS FOR TREATING BLEEDING DISORDERS USING A PLATELET SUBPOPULATION - The present invention relates to a platelet subpopulation with high binding capacity to recombinant activated factor VII (rFVIIa), and its use for the treatment of bleeding disorders and for determining whether a subject is a candidate for treatment with rFVIIa. | 10-02-2014 |
20140341874 | DEXTRAN-BASED TISSUELETTE CONTAINING PLATELET-RICH PLASMA LYSATE FOR CARTILAGE REPAIR - The invention relates to a dextran-based tissuelette comprising platelet-rich plasma lysate (PRPL), which can be used for tissue repair. In particular, the tissuelette of the present invention can be adapted to display properties similar to natural cartilage, while having increased chondrocyte-attraction. Also, it has a tunable biostability that allows for degradation of the tissuelette material during natural tissue regeneration. In addition, the tissuelette displays full and covalent integration with the surrounding tissue when prepared directly at the site requiring tissue repair. The tissuelette of the present invention is primarily meant for use in cartilage repair, in particular cartilage repair upon degradation by osteoarthritis. | 11-20-2014 |
20140348810 | ABSORBABLE IN SITU GEL-FORMING SYSTEM, METHOD OF MAKING AND USE THEREOF - An in situ gel-forming composition is disclosed. The in situ gel-forming composition comprises one or more absorbable polymers, solvents such as N-methyl-2-pyrrolidone, polyethylene glycol or DMSO, and optionally one or more bioactive agent. The composition forms a hydrogel or semi-solid mass on contact with an aqueous environment. The method of using in situ gel-forming composition for various applications is also disclosed. | 11-27-2014 |
20140363412 | PLATELET ACTIVATION USING LONG ELECTRIC FIELD PULSES - Embodiments of the disclosure relate to platelet activation and/or aggregation using electric pulses. In one embodiment, a platelet-containing sample is exposed to electric pulses. At least one of the electric pulses has a duration greater than 1 microsecond and a field strength below 50 kV/cm. In another embodiment, the electric pulses may be designed with particular field strengths and durations. | 12-11-2014 |
20150017145 | Pharmaceutical Kits Comprising Mesenchymal Stem Cells - A method of treating a natural soft skeletal tissue injury in a patient the method comprising administering to the patient a composition of mesenchymal stem cells in liquid suspension enriched compared to the natural source of said cells, or tenocytes derived therefrom. The method is particularly suited to the regeneration of tendons in competitive mammals, such as the superficial digital flexor tendon of the horse. | 01-15-2015 |
20150030578 | METHOD FOR PRODUCING ACTIVATED AUTOLOGOUS PLATELET RICH AND PLATELET POOR PLASMA AND METHODS OF USE - A method and kit to produce activated autologous platelet rich and platelet poor plasma (AAPRPP) and methods of use to treat pain. The method to produce AAPRPP generally comprising (1) obtaining whole blood from patient; (2) centrifuging whole blood in a collection tube; (3) extracting platelet rich and platelet poor plasma mixture from collection tube; and (4) transferring platelet rich and platelet poor plasma mixture to an activation tube containing at least one platelet aggregator and at least one platelet activator to obtain a resulting platelet concentration. The method to treat pain generally comprising producing AAPRPP and extracting contents of activation tube into a standard syringe then injecting AAPRPP at or near the nerve group responsible for the affected anatomical area. | 01-29-2015 |
20150050257 | FIBROSIS CAUSING AGENT - A fibrosis-causing agent is highly effective in the fibrosis of tissues. The fibrosis-causing agent contains a fibrosis inducer and a fibrosis promoter. A fibrosis-causing agent dosage form and a method of administering the fibrosis-causing agent is also disclosed. | 02-19-2015 |
20150071893 | THERAPEUTIC PREPARATION AND PROCESS FOR PREPARING SIAD THERAPEUTIC PREPARATION - Provided is a therapeutic preparation including a substance including ozone and a proteic substance. Also provided are methods of treating a disorder in a bovid, including administering to a subject in need thereof, a therapeutically effective amount of the therapeutic preparation. | 03-12-2015 |
20150093367 | ACUPOINT INJECTION THERAPY USING AN ENRICHED CELLULAR MIXTURE - A system and method are provided that use the meridian flow defined in traditional Chinese medicine to target specific regions of the body to treat certain health conditions. A cellular mixture is injected into the body via an acupoint on a particular meridian in order to deliver the mixture to an organ or body region associated with the particular meridian. The cellular mixture can be a stem cell/PRP mixture. | 04-02-2015 |
20150104436 | APPLICATION AND PHARMACEUTICAL COMPOSITION OF PREACTIVATED AND DISAGGREGATED SHAPE-CHANGED PLATELETS - Preactivated and disaggregated shape-changed platelets, fixed shape-changed platelets, and a pharmaceutical composition thereof are used for treating acute and emergent inflammatory disease in a dosage of 1×10 | 04-16-2015 |
20150118210 | COMPOSITION FOR ENHANCING CELL ENGRAFTMENT AND HOMING PROPERTIES CONTAINING PRP AS ACTIVE INGREDIENT - The present invention provides a composition for enhancing cell engraftment and homing properties, containing platelet-rich plasma (PRP) as an active ingredient. The present invention provides a method for improving cell engraftment and homing properties, comprising the step of treating in vitro isolated cells with a composition containing PRP as an active ingredient. According to the present invention, when a cell to be transplanted or a region to which cells are transplanted is treated with PRP, or a cell to be transplanted is mixed with PRP, transplantation to an in vivo region is carried out, thereby increasing cell engraftment in a transplanted region and increasing cell homing from a transplanted region to a damaged region. | 04-30-2015 |
20150125436 | PROCESS, TUBE AND DEVICE FOR THE PREPARATION OF WOUND HEALANT COMPOSITION - The present invention is related to the field of tissue regeneration. It concerns more particularly new processes, tubes and devices for thrombin, platelet concentrate and wound healant preparations, alone or in combination with cell extracts, cell compositions and uses thereof. | 05-07-2015 |
20150313944 | METHODS FOR PRODUCTION OF PLATELETS FROM PLURIPOTENT STEM CELLS AND COMPOSITIONS THEREOF - Methods for production of platelets from pluripotent stem cells, such as human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) are provided. These methods may be performed without forming embryoid bodies or clusters of pluripotent stem cells, and may be performed without the use of stromal inducer cells. Additionally, the yield and/or purity can be greater than has been reported for prior methods of producing platelets from pluripotent stem cells. Also provided are compositions and pharmaceutical preparations comprising platelets, preferably produced from pluripotent stem cells. | 11-05-2015 |
20150335682 | PRODUCTION OF RED BLOOD CELLS AND PLATELETS FROM STEM CELLS - This disclosure provides methods of making a megakaryocyte-erythroid progenitor cell (MEP), comprising differentiating a stem cell into a MEP in culture in the presence of an aryl hydrocarbon receptor (AhR) agonist. In some embodiments the stem cell is a pluripotent stem cell. In some embodiments the MEP co-expresses CD41 and CD235. In some embodiments the number of MEPs produced in the culture increases exponentially. Methods of making a red blood cell (RBC) by culturing a MEP in the presence of an AhR agonist are also provided. Methods of making a megakaryocyte and/or a platelet, comprising culturing a MEP in the presence of an AhR modulator are also provided. In some embodiments the AhR modulator is an AhR antagonist. This disclosure also provides compositions comprising at least 1 million MEPs per ml and compositions in which at least 50% of the cells are MEPs. | 11-26-2015 |
20150366912 | APPLICATION AND PHARMACEUTICAL COMPOSITION OF PREACTIVATED AND DISAGGREGATED SHAPE-CHANGED PLATELETS - Preactivated and disaggregated shape-changed platelets, fixed shape-changed platelets, and a pharmaceutical composition thereof are used for treating acute and emergent inflammatory disease in a dosage of 1×10 | 12-24-2015 |
20160002598 | DEVICE AND METHODS FOR PLATELET LYSIS OR ACTIVATION - Device, system and method embodiments are disclosed herein which provide for the production of a modified autologous platelet solution at the patient bedside for contemporaneous reinjection to the patient. In certain embodiments all of the steps including, but not limited to blood draw, platelet lysis, solution preparation and reinjection to a patient may be accomplished in a single office or clinic visit without relocating the patient. Accordingly, the apparatus, devices and systems disclosed herein generally include a substantially stand-alone machine, device or system which is configured to accept a platelet containing solution, induce lysis of one or more platelet bodies within the platelet containing solution and provide the resulting modified platelet solution in a manner suitable for injection into the patient. | 01-07-2016 |
20160003845 | Method and Biomarkers for the Detection of Dengue Hemorrhagic Fever - The present invention provides compositions and methods for detecting, analyzing, and identifying biomolecules used to diagnose patient with risk of DHF. More particularly, the invention provides plasma biomarkers including complement factor D to complement factor H (FactorD/FactorH) ratio and levels of one or more of IL2, desmoplakin, and high molecular weight albumin, which are used to detect risk of developing DHF. | 01-07-2016 |
20160015721 | Compositions and Methods for Cartilage Repair - Autologous compositions and methods are provided for cartilage repair in patients in need thereof. Some aspects include combinations of platelet-based materials with chondrogenesis inducing agents in the presence or absence of cell-based therapies. | 01-21-2016 |
20160022736 | METHODS FOR PRODUCTION OF PLATELETS FROM PLURIPOTENT STEM CELLS AND COMPOSITIONS THEREOF - Methods for production of platelets from pluripotent stem cells, such as human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) are provided. These methods may be performed without forming embryoid bodies or clusters of pluripotent stem cells, and may be performed without the use of stromal inducer cells. Additionally, the yield and/or purity can be greater than has been reported for prior methods of producing platelets from pluripotent stem cells. Also provided are compositions and pharmaceutical preparations comprising platelets, preferably produced from pluripotent stem cells. | 01-28-2016 |
20160051586 | METHODS OF GROWING AND PREPARING STEM CELLS AND METHODS OF USING THE SAME - The present invention relates to methods of improving stem cell delivery to a subject in need thereof and kits designed to assist in such. The methods comprise interchangeably allowing or promoting cell growth in conditions that permit three-dimensional growth, such as with a bioreactor, utilizing allogeneic, autologous or xenogeneic cells, mixing the cells with platelet rich plasma that is autologous, allogeneic or xenogeneic to the subject, and site specific delivery of between about three and ten million activated stem cells per kilogram of the subject receiving the treatment. | 02-25-2016 |
20160051587 | INTERNAL MEDICINE DOSING OF STEM CELLS - The present invention relates to methods of improving stem cell delivery to a subject in need thereof and kits designed to assist in such. The methods comprise site specific delivery of between five and fifteen million stem cells at the site and systemic administration of between about three and ten million cells per kilogram of the subject receiving the treatment. | 02-25-2016 |
20160166645 | TREATMENT OF COLLAGEN DEFECTS USING PROTEIN SOLUTIONS | 06-16-2016 |